Best Clinical Genomics Companies in England, United Kingdom
The 71 best Clinical Genomics companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inivata.
Ranked: Best Clinical Genomics companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Inivata Developer of liquid biopsy platform for detecting cancer | $189M | 64 mo ago | 81 | Davina Gale Co-founder | Acquired | — | 97 patents Liquid biopsy and nucleic‑acid analysis for cancer detection and monitoring. | — |
| 2 | ReViral Developer of antiviral compounds for RSV | $121M | 69 mo ago | 28 | Khattereh Ahmadi Co-Founder | Acqui-Hired | — | 91 patents Antiviral benzodiazepine derivatives for treating respiratory syncytial virus infections | — |
| 3 | Microbiotica Developer of live bacterial therapeutics and biomarkers for multiple diseases | $83M | 51 mo ago | 42 42 → 55 (+31%) · sector median +31% | Gordon Dougan Co-Founder | Series B | Top 10M | 30 patents Engineered therapeutic bacterial formulations for microbiome-based disease treatment | 1 award |
| 4 | QuantuMDx Group Manufacturer of molecular diagnostic platforms and assays for infectious diseases | $57M | 46 mo ago | 98 98 → 53 (-46%) · sector median +31% | Jonathan Halloran CEO & ex-Co-Founder | Series D | Top 10M | 154 patents Microfluidic nucleic‑acid diagnostic platforms for rapid qPCR and sample‑prep automation | — |
| 5 | Blue Earth Diagnostics Developer of radioactive molecular imaging agents for cancer | $49M | 131 mo ago | 38 | — | Acquired | Top 10M | 44 patents Radiopharmaceutical PET agents for imaging and therapy of FAP and bone lesions | — |
| 6 | Sano Provider of clinical trial recruitment and genetic testing research services | $26M | 29 mo ago | 10 | Patrick Short Co-Founder & CEO | Series A | Top 5M | — | — |
| 7 | Treos Bio Developer of cancer vaccines and companion diagnostics | $22M | 62 mo ago | 12 12 → 16 (+33%) · sector median +31% | — | Series B | — | 65 patents Personalized peptide-based cancer vaccines and immunogenic peptide discovery platforms | — |
| 8 | Suisse Life Science Direct to consumer genetic profiling and associated services | $20M | 96 mo ago | — | Omar Fogliadini Founder & CEO | Acquired | — | — | — |
| 9 | 14M Genomics Provider of a technology that utilizes next gen sequencing and proprietary analytics for cancer diagnostics | $20M | 138 mo ago | 20 | — | Deadpooled | — | — | — |
| 10 | Yourgene Health Provider of non-invasive prenatal genetic tests and genomic services | $15M | 86 mo ago | 253 253 → 169 (-33%) · sector median +31% | — | Public | — | — | — |
| 11 | Valirx Developer of novel technologies and products in oncology therapeutics and diagnostics | $14M | 84 mo ago | 7 | — | Public | — | 16 patents Patents concentrated in chemistry & materials | 2 partnerships |
| 12 | Cytox Developer for prognostic tests for assessing the risk of dementia | $12M | 82 mo ago | 12 | — | Series B | — | — | — |
| 13 | Oxford Biodynamics Developer of personalized diagnostics by identifying biomarkers through epigenetics | $11M | 37 mo ago | 39 39 → 55 (+41%) · sector median +31% | Jon Burrows CEO | Public | Top 10M | 224 patents Chromosome conformation capture diagnostics for cancer detection and biomarker discovery | 1 job opening |
| 14 | Base Genomics Provider of in-vitro DNA methylation based detection test for early stage of cancer | $11M | 72 mo ago | 19 | Chunxiao Song Co-Founder | Acqui-Hired | — | — | — |
| 15 | Genedrive Provider of point of care molecular diagnostics platform for genotyping and sequence analysis | $9M | 14 mo ago | 43 43 → 45 (+5%) · sector median +31% | Christopher Potten Co-Founder | Public | Top 10M | — | 1 partnership |
| 16 | Tagomics Developer of genomic-based cancer diagnostic platform | $8M | 12 mo ago | 8 | — | Series A | Top 50M | 13 patents Epigenetic and biomolecular profiling technologies for nucleic acid modification analysis | 1 job opening |
| 17 | Lumora Developer of molecular diagnostics for infectious diseases | $7M | 159 mo ago | 19 | Laurence Tisi Co-Founder | Acqui-Hired | — | 47 patents Rapid isothermal nucleic acid amplification and sample preparation technologies | — |
| 18 | ArquerDx Develops urine-based immunoassay tests for genitourinary cancers. | $5M | 86 mo ago | 9 | — | Series A | — | — | — |
| 19 | Cambridge Cancer Genomics Developer of AI-based precision medicine tools for oncologists | $5M | 90 mo ago | 16 | — | Acqui-Hired | — | — | — |
| 20 | Oxford Cancer Biomarkers Developer of biomarker diagnostics for cancer therapies | $5M | 38 mo ago | 12 | Nicholas Barrie La Thangue Co-Founder & CEO | Series B | — | 12 patents Quantitative histopathology tissue analysis for solid tumor cancer diagnostics | — |
| 21 | GEN inCode Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring | $4M | 30 mo ago | 26 26 → 47 (+81%) · sector median +31% | — | Public | Top 50M | — | — |
| 22 | Circulogene Developed cell-free DNA liquid biopsy tests for cancer | $4M | 39 mo ago | 51 51 → 40 (-22%) · sector median +31% | Michael Mullen Chairman and CEO | Series A | Top 50M | — | — |
| 23 | ReadyGo Provider of diagnostic test and sample collection tools for research labs | $3M | 15 mo ago | 8 | Elaine Warburton Co-Founder | Seed | Top 50M | — | — |
| 24 | Fluoretiq Developer of a diagnostic platform for bacterial identification | $2M | 52 mo ago | 9 | — | Seed | — | 4 patents Fluorescence-based detection probes for cellular materials and bacterial spectrofluorometry | 1 launch |
| 25 | Omixy Complete -omics profile | $2M | 127 mo ago | 12 | — | Deadpooled | — | — | — |
| 26 | Micropathology Provider of services for the rapid diagnosis and management of infectious and genetic disease, | $1M | 77 mo ago | — | David Burnett Co-Founder | Funding Raised | — | — | — |
| 27 | Luas Diagnostics Developer of sensors and connected app for diabetes management | $949K | 38 mo ago | 3 | — | Seed | — | — | — |
| 28 | Mursla Provider of diagnostic device for cancer detection | $547K | 69 mo ago | 9 | Victor Serdio Co-Founder | Seed | Top 50M | 32 patents Isolation, characterization, and biosensor conditioning of tissue-specific extracellular vesicles. | 1 award |
| 29 | Molmart Provider of genetic testing services | $381K | 26 mo ago | 4 | Markella Mikkelsen Founder | Seed | — | — | — |
| 30 | Odin Vision Provider of AI-based colon cancer detection platform | $368K | 85 mo ago | 12 | — | Acquired | Top 50M | — | — |
| 31 | Qbiotix Developer of nucleic acid-based assays for microbial disease detection | $309K | 75 mo ago | — | William Addison Founder | Seed | — | 18 patents Patents concentrated in chemistry & materials | — |
| 32 | Elucigene Provider of in vitro diagnostics for cystic fibrosis and other genetic diseases | $263K | 140 mo ago | 180 | Mark Street-Docherty CEO | Acquired | — | — | — |
| 33 | Cambridge Protein Arrays Developer of DNA microarray to protein microarray(DAPA) platform | $120K | 113 mo ago | 2 | — | Funding Raised | — | — | — |
Top 12 Clinical Genomics companies in England
#1
Series A · Birmingham, England · founded 2020 · 8 employees$8.4Mraised▾
Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer.
- Jun 2025Grant (prize money)$1.2M
- Feb 2024Series A$8.4M
#2
Public · Manchester, England · founded 2000 · 43 employees$9.3Mraised▾
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis. The company offers MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, and Genedrive HCV ID Kit is used to screen for hepatitis C and COVID-19.
- Apr 2025Post IPO$1.6M
- Nov 2018Post IPO$7.7M
#3
Seed · Bath, England · founded 2020 · 8 employees$3.2Mraised▾
Provider of diagnostic test and sample collection tools for research labs. The company offers a sample collection product called "Snap" and a diagnostic testing product called "Snapshot". Also, offers a rapid test platform for small laboratories, pharmacies, and off-grid diagnostic requirements.
- Mar 2025Seed$644.5K
- Jul 2022Seed$1.8M
- Feb 2022Seed$297.4K
- Mar 2021Seed$1.2M
#4
Series A · London, England · founded 2016 · 10 employees$26.5Mraised▾
Provider of clinical trial recruitment and genetic testing research services. The platform combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.
- Jan 2024Series A$11.4M
- Aug 2023Grant (prize money)$419.3K
- Mar 2022Series A$11M
- Jan 2021Seed$3.4M
#5
Series D · Newcastle Upon Tyne, England · founded 2008 · 98 employees$57.3Mraised▾
Manufacturer of molecular diagnostic platforms and assays for infectious diseases. The company's product portfolio centers on a rapid, portable PCR platform and a growing suite of multiplex molecular assays designed for point‑of‑care and near‑patient testing.
- Aug 2022Series D$19.2M
- Mar 2021Series C$15.2M
- Jan 2018Series B$12M
- Oct 2016Series A$2.5M
#6
Acquired · Cambridge, England · founded 2014 · 81 employees$188.8Mraised▾
Developer of liquid biopsy platform for detecting cancer. The company's technology allows improving sensitivity and coverage of larger gene panels compared to traditional methods. Inivata’s proprietary platform TAm-Seq provides the ability to conduct next-generation sequence analysis of sizable genomic regions including entire genes or exons. Its gene panel includes a profile of 34 different cancer-related genes.
- Feb 2021Series C$35M
- May 2020Series C$49.5M
- Aug 2018Series B$52.8M
- Jan 2017Grant (prize money)—
#7
Series B · Cambridge, England · founded 2016 · 42 employees$82.8Mraised▾
Developer of live bacterial therapeutics and biomarkers for multiple diseases. The company identifies gut bacteria linked to phenotype with unprecedented precision to discover and develop live bacterial therapeutics and biomarkers for Inflammatory bowel disease, Immuno-oncology, and Gut Epithelial Barrier Repair.
- Mar 2022Series B$67M
- May 2018Series A$5.4M
- Dec 2016Series A$10.4M
#8
Public · Oxford, England · founded 2007 · 39 employees$11Mraised▾
Developer of personalized diagnostics by identifying biomarkers through epigenetics. Its proprietary platform EpiSwitch provides the early detection of aberrant gene expression in very low copy numbers and in a small sample of abnormal cells, at the early stage of the disease. The test is non-invasive used for Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Breast Cancer, Diabetes Type I (T1DM), and others.
- May 2023Grant (prize money)$963K
- Oct 2022Post IPO—
- Nov 2021Post IPO$5M
- Aug 2021Grant (prize money)$910K
#9
Public · Manchester, England · founded 2018 · 26 employees$4.5Mraised▾
GEN inCode is a developer of precision medicines by combining genetic and clinical data for cardiac disease monitoring. It provides solutions for the prevention and treatment of cardiovascular disease risk. The models are based on algorithms and machine learning which allows doctors to accurately measure and assess a patient's clinical and genetic risk.
- Dec 2023Post IPO$5.1M
- Aug 2021Post IPO$694.9K
- Jul 2020Series A$4.5M
- Jan 2020Seed$982.1K
#10
Acqui-Hired · London, England · founded 2011 · 28 employees$121Mraised▾
Developer of antiviral compounds for RSV. The company is developing its lead candidate RV521 as an antiviral therapy for Respiratory Syncytial Virus (RSV), which is an infection that often leads to asthma, COPD, and/or pneumonia.
- Aug 2020Series C$44M
- Aug 2018Series B$55M
- Jul 2018Series B$55M
- Sep 2015Series A$21M
#11
Series A · Birmingham, England · founded 2015 · 51 employees$4.3Mraised▾
Circulogene Theranostics delivers tumor monitoring in droplets of blood through patented liquid biopsy process. Launched its cell-free DNA (cfDNA) liquid biopsy tests for 10 tumor types including breast, lung and colon cancer. The tools, which screen for circulating cfDNA from a single drop of blood, allow doctors to plan and monitor treatment after a patient gets a cancer diagnosis.
- Mar 2023Conventional Debt$2M
- Aug 2022Conventional Debt$2.6M
- Jan 2021Conventional Debt$250K
- Sep 2019Conventional Debt$330K
#12
Series B · Oxford, England · founded 2011 · 12 employees$4.6Mraised▾
Developer of biomarker diagnostics for cancer therapies. Its proprietary platform CancerNav is a genome-wide functional screen for gene-targeted drugs for cancer. Its other platform ToxNav is for predicting drug toxicity effects of lead compounds. Oxford Cancer Biomarkers offers a panel of diagnostic, prognostic tests, and pharmacogenomic tests for colorectal cancer developed on its platforms.
- Apr 2023Series B—
- Dec 2015Series B—
- Jan 2012Series A$4.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Diagnostics in England is moving
A read on the academic research around Diagnostics in England — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 66 papers.
- Public Health England38
- New England Biolabs6
- Hunter New England Local Health District4
- Genomics England4
- University of the West of England4
- Point-of-care testing5
- Virology3
- Workflow2
- Computational biology2
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2
- Point-of-care testing13
- Point of care7
- Chlamydia trachomatis4
- Test (biology)3
- Nucleic Acid Amplification Tests3
- Point-of-care testing5→8
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.